In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Thursday, January 7

Friday, january 8

Saturday, January 9

sunday, january 10

Thursday, January 7

REGISTRATION

3-9 p.m. | Indigo West Foyer CD

WELCOME AND OPENING Keynote

5-6:30 p.m. | Indigo CG

  • 5 p.m. | Welcome and Conference Introduction
    David R. Piwnica-Worms, The University of Texas MD Anderson Cancer Center, Houston, Texas  
  • 5:30 p.m. | Opening Keynote Lecture
    Theranostics revolution: Seeing, targeting, treating
    Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, New York            

Opening Reception

6:30-7:30 p.m. | Promenade Plaza

Friday, January 8

continental breakfast

7-8:30 a.m. | Indigo Terrace

Roundtables Networking Session

7:15-8:15 a.m. | Indigo Terrace

Plenary Session 1: Reframing the Tumor Microenvironment in Radiotheranostics

8:30-10:15 a.m. | Indigo CG

Session Chair: David R. Piwnica-Worms, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 8:35 a.m. | Immunological Signatures of Radioligand Therapy
    David R. Piwnica-Worms
  • 8:55 a.m. | Immuno-radiobiological effects of radiopharmaceutical therapies in the tumor microenvironment
    Zachary Morris, University of Wisconsin-Madison School of Medicine & Public Health, Madison, Wisconsin
  • 9:15 a.m. | Targeting stroma to overcome therapeutic resistance in solid tumors
    Ellen Pure, University of Pennsylvania, Philadelphia, Pennsylvania
  • 9:35 a.m. | Short talk selected from proffered abstract
  • 9:45 a.m. | Short talk selected from proffered abstract
  • 9:55 a.m. | Panel Discussion/Q&A

Break

10:30-10:45 a.m. | Indigo West Foyer CD

Plenary Session 2: New Frontiers in Radiotheranostic Development

10:45 a.m.-12:45 p.m. | Indigo CG

Session Chair: Julie L. Sutcliffe, University of California, Davis, California

  • 10:50 a.m. | 80 Years of Theranostics at the University of Michigan
    Peter JH Scott, University of Michigan Medical School, Ann Arbor, Michigan
  • 11:10 a.m. | Novel theranostic radionuclides and potential use
    Cathy Cutler, Brookhaven National Laboratory, Rochester, New York
  • 11:30 a.m. | Heather Jacene, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11:50 a.m. | Short talk selected from proffered abstract
  • 12 p.m. | Short talk selected from proffered abstract
  • 12: 10 p.m. | Panel Discussion/Q&A

Lunch on own

12:45-2:30 p.m.

Plenary Session 3: From Discovery to Patient Care: Clinical Translation in Radioligand Therapy

2:30-4:30 p.m. | Indigo CG

Session Chair: To be announced

  • 2:35 p.m. | Translation of novel radioligand therapy into the clinic
    Andrew Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
  • 2:55 p.m. | Radiopharmaceuticals as a Safe and Promising Strategy to Address the Standard of Care Bottleneck
    Elcin Zan, Cleveland Clinic, Cleveland, Ohio
  • 3:15 p.m. | Learning from imaging protein-based agents in patients to guide precision oncology
    Elisabeth de Vries, University Medical Center Groningen, Groningen, Netherlands
  • 3:35 p.m.| Short talk selected from proffered abstract
  • 3:45 p.m. | Short talk selected from proffered abstract
  • 3:55 p.m. | Panel Discussion/Q&A

Break

4:30-4:45 p.m. | Indigo West Foyer CD

Panel Discussion: Forging Academic, Industry, and Government Partnerships

4:45-5:45 p.m. | Indigo CG

Moderator: To be announced

  • Panelists
    Aruna Korde, International Atomic Energy Agency, Vienna, Austria
    Pushpa Tandon, NCI, Rockville, Maryland
    Freddy E. Escorcia, RayzeBio, San Diego, California
    Jeevan Virk, Sego Therapeutics, Salt Lake City, Utah
    Serge Layschenko, Juniper Biosciences, Bridgewater, New Jersey

Poster Session A/Reception

5:45-6:45 p.m.

Saturday, June 9

continental breakfast

7-8:30 a.m. | Indigo Terrace

Roundtables Networking Session

7:15-8:15 a.m. | Indigo CG

Plenary Session 4: Radiotheranostics at the Interface of Cancer and Immunity

8:30 -10:30 a.m. | Indigo CG

Session Chair: Lawrence Fong, Fred Hutch Cancer Center, Seattle, Washington

  • 8:35 a.m. | Combining different radiotherapy modalities with immune checkpoint inhibition in prostate cancer     
    Lawrence Fong
  • 8:55 a.m. | Targeting the mitochondrial checkpoint to enhance the immunogenicity of radiotherapy
    Lorenzo Galluzzi, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 9:15 a.m. | Targeting CCR8-positive tumor-infiltrating Tregs with alpha- and beta-radioimmunotherapy in colorectal cancer and beyond
    Ekaterina Dadachova, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
  • 9:35 a.m. | Short talk selected from proffered abstract
  • 9:45 a.m. | Short talk selected from proffered abstract
  • 9:55 a.m. | Panel Discussion/Q&A

Break

10:30-10:45 a.m. | Indigo West Foyer CD

Plenary Session 5: Systems-Level Insights into Response and Resistance    

10:45 a.m.-12:45 p.m. | Indigo CG

Session Chair: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

  • 10:50 a.m. | Metabolic reprogramming and cancer progression: What should we look for and how can we see it?
    Ralph J. Deberardinis, UT Southwestern Medical Center, Dallas, Texas
  • 11:10 a.m. | From targeting PIKK kinases for radiosensitization to the development of a novel theranostic target
    Michael Kastan, Duke University, Durham, North Carolina
  • 11:30 a.m. | Immune priming by β-radioligand therapy reveals spatial immune memory niches
    Margie Sutton, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:50 a.m. | Short talk selected from proffered abstract
  • 12 p.m. | Short talk selected from proffered abstract
  • 12:10 p.m. | Panel Discussion/Q&A

Lunch on own

12:45-2:30 p.m.

Plenary Session 6: Molecular Imaging as a Window into Treatment Response

2:30-4:30 p.m. | Indigo CG

Session Chair: Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York, New York

  • 2:35 p.m. | Kayvan R. Keshari
  • 2:55 p.m. | Combination strategies for dual tumor and stoma theranostics
    Edwinn C. Pratt, Stony Brook University, Renaissance School of Medicine, New York, New York
  • 3:15 p.m. | Molecular imaging of therapy response by PET
    Eric Aboagye, Imperial College London, London, United Kingdom
  • 3:35 p.m.| Short talk selected from proffered abstract
  • 3:45 p.m. | Short talk selected from proffered abstract
  • 3:55 p.m. | Panel Discussion/Q&A

Break

4:30-4:45 p.m. | Indigo West Foyer CD

Panel Discussion: Who Owns Radioligand Therapy? Rethinking Training and Clinical Identity

4:45-5:45 p.m. | Indigo CG

Moderator: David Mankoff, University of Pennsylvania, Philadelphia, Pennsylvania

  • Panelists
    Julian Adams, Stand Up To Cancer (SU2C), Los Angeles, California
    Douglas R. Spitz, University of Iowa, Iowa City, Iowa
    Freddy E. Escorcia, RayzeBio, San Diego, California
    Jason Lewis, Memorial Sloan Kettering Cancer Center, New York, New York
    Additional panelists to be announced

Poster Session B/Reception

5:45-7:45 p.m.

Sunday, January 10

continental breakfast

7-8 a.m. | Indigo Terrace

Plenary Session 7: Preparing the Next Generation of Radiotheranostics Leaders

8-10 a.m. | Indigo CG

Session Chair: David Mankoff, University of Pennsylvania, Philadelphia, Pennsylvania

  • 8:05 a.m. | Enhancing the workforce for theranostics practice and research: radiopharmaceutical training for physicians and physician-scientists
    David Mankoff
  • 8:25 a.m. | Michael Overholtzer, Memorial Sloan Kettering Cancer Center, New York, New York
  • 8:45 a.m. | Panel Discussion/Q&A

Break

9:15-9:30 a.m. | Indigo West Foyer CD

Closing Keynote Lecture

9:30-10:30 a.m. | Indigo CG
Session Chair: Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York, New York

  • 9:35 a.m. | Julie L. Sutcliffe, University of California, Davis, California

Closing Remarks

10:30-10:45 a.m. | Indigo CG

  • Kayvan R. Keshari, Memorial Sloan Kettering Cancer Center, New York, New York